(0.08%) 5 521.50 points
(0.13%) 39 894 points
(0.19%) 19 788 points
(-0.01%) $81.62
(0.60%) $2.83
(-0.30%) $2 337.40
(0.17%) $29.58
(0.27%) $1 004.50
(0.00%) $0.931
(-0.07%) $10.53
(-0.01%) $0.788
(-0.85%) $87.25
0.00% $ 0.0812
Live Chart Being Loaded With Signals
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally...
Stats | |
---|---|
Dzisiejszy wolumen | 24.21M |
Średni wolumen | 5.97M |
Kapitalizacja rynkowa | 0.00 |
EPS | $-0.390 ( Q3 | 2022-11-09 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.0390 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0770 (94.83%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-11-01 | Gross Paul Edward | Buy | 4 625 | Common Stock |
2022-11-01 | Gross Paul Edward | Buy | 5 623 | Common Stock |
2022-11-02 | Gross Paul Edward | Sell | 2 135 | Common Stock |
2022-11-02 | Gross Paul Edward | Sell | 2 595 | Common Stock |
2022-11-01 | Gross Paul Edward | Sell | 4 625 | Restricted Stock Units |
INSIDER POWER |
---|
-6.25 |
Last 100 transactions |
Buy: 146 624 | Sell: 133 052 |
Wolumen Korelacja
Clovis Oncology, Inc. Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
RXRAW | 0.853 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Clovis Oncology, Inc. Korelacja - Waluta/Towar
Clovis Oncology, Inc. Finanse
Annual | 2021 |
Przychody: | $148.76M |
Zysk brutto: | $109.93M (73.90 %) |
EPS: | $-2.18 |
FY | 2021 |
Przychody: | $148.76M |
Zysk brutto: | $109.93M (73.90 %) |
EPS: | $-2.18 |
FY | 2020 |
Przychody: | $164.52M |
Zysk brutto: | $123.22M (74.89 %) |
EPS: | $-4.38 |
FY | 2019 |
Przychody: | $143.01M |
Zysk brutto: | $108.32M (75.75 %) |
EPS: | $-7.43 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Clovis Oncology, Inc.
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. On December 11, 2022, Clovis Oncology, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej